首页 > 最新文献

Eurosurveillance最新文献

英文 中文
Genomic epidemiological analysis of a single-centre polyclonal outbreak of Serratia marcescens, Belgium, 2022 to 2023. 2022 - 2023年比利时粘质沙雷菌单中心多克隆暴发的基因组流行病学分析
IF 9.9 2区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-11-01 DOI: 10.2807/1560-7917.ES.2024.29.48.2400144
Sam Van Goethem, Basil Britto Xavier, Youri Glupczynski, Matilda Berkell, Philippe Willems, Bruno Van Herendael, Katrien Hoet, Katleen Plaskie, Daan Van Brusselen, Herman Goossens, Surbhi Malhotra-Kumar

Serratia marcescens is an opportunistic pathogen with a propensity to cause nosocomial outbreaks, particularly in neonatal intensive care units (NICUs). We present a sustained outbreak spanning over 18 months (1 January 2022-29 August 2023) in a NICU in Antwerp, Belgium, affecting 61 neonates, identified through samples taken for diagnostic purposes and by rectal screening. Ten neonates were infected: five with lower respiratory tract infection, four with conjunctivitis and one fatal case with sepsis. In a logistic regression analysis, nursing in an incubator was significantly associated with acquisition of S. marcescens (odds ratio (OR): 2.99; 95% confidence interval (CI): 1.14-8.25; p < 0.05). Whole genome sequencing-based multilocus sequence typing (wgMLST) and core genome single nucleotide polymorphism (cgSNP) analysis of isolates from clinical (n = 4), screening (n = 52) and environmental samples (n = 8), identified eight clusters and five singletons not associated with the clusters. Although outbreak measures were successful in containing further spread within the ward during sudden surges when > 4 cases per week were identified (peak events), several peaks with different clonal clusters occurred. The emergence of similar outbreaks in Belgian hospitals underscores the need of continuous surveillance and NICU-specific infection prevention and control (IPC) measures.

粘质沙雷氏菌是一种机会性病原体,有引起院内暴发的倾向,特别是在新生儿重症监护病房(NICUs)。我们在比利时安特卫普的一个新生儿重症监护室报告了一次持续爆发,持续时间超过18个 月(2022年1月1日至2023年8月29日),影响了61名新生儿,这些新生儿是通过为诊断目的采集的样本和直肠筛查确定的。10例新生儿感染:5例下呼吸道感染,4例结膜炎,1例败血症死亡。在logistic回归分析中,培养箱中的护理与粘质链球菌的获得显著相关(优势比(OR): 2.99;95%置信区间(CI): 1.14-8.25;P 每周鉴定4例(峰值事件),出现多个不同克隆聚集的峰值。比利时医院出现的类似疫情凸显了持续监测和针对新生儿重症监护室的感染预防和控制措施的必要性。
{"title":"Genomic epidemiological analysis of a single-centre polyclonal outbreak of <i>Serratia marcescens</i>, Belgium, 2022 to 2023.","authors":"Sam Van Goethem, Basil Britto Xavier, Youri Glupczynski, Matilda Berkell, Philippe Willems, Bruno Van Herendael, Katrien Hoet, Katleen Plaskie, Daan Van Brusselen, Herman Goossens, Surbhi Malhotra-Kumar","doi":"10.2807/1560-7917.ES.2024.29.48.2400144","DOIUrl":"10.2807/1560-7917.ES.2024.29.48.2400144","url":null,"abstract":"<p><p><i>Serratia marcescens</i> is an opportunistic pathogen with a propensity to cause nosocomial outbreaks, particularly in neonatal intensive care units (NICUs). We present a sustained outbreak spanning over 18 months (1 January 2022-29 August 2023) in a NICU in Antwerp, Belgium, affecting 61 neonates, identified through samples taken for diagnostic purposes and by rectal screening. Ten neonates were infected: five with lower respiratory tract infection, four with conjunctivitis and one fatal case with sepsis. In a logistic regression analysis, nursing in an incubator was significantly associated with acquisition of <i>S. marcescens</i> (odds ratio (OR): 2.99; 95% confidence interval (CI): 1.14-8.25; p < 0.05). Whole genome sequencing-based multilocus sequence typing (wgMLST) and core genome single nucleotide polymorphism (cgSNP) analysis of isolates from clinical (n = 4), screening (n = 52) and environmental samples (n = 8), identified eight clusters and five singletons not associated with the clusters. Although outbreak measures were successful in containing further spread within the ward during sudden surges when > 4 cases per week were identified (peak events), several peaks with different clonal clusters occurred. The emergence of similar outbreaks in Belgian hospitals underscores the need of continuous surveillance and NICU-specific infection prevention and control (IPC) measures.</p>","PeriodicalId":12161,"journal":{"name":"Eurosurveillance","volume":"29 48","pages":""},"PeriodicalIF":9.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11605797/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142750264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An in-depth analysis of antimicrobial prescription quality in 10 non-university hospitals, in southwest Germany, 2021. 2021 年对德国西南部 10 家非大学医院抗菌药物处方质量的深入分析。
IF 9.9 2区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-11-01 DOI: 10.2807/1560-7917.ES.2024.29.46.2400156
Gesche Först, Roland Giesen, Geertje Fink, Matthias Sehlbrede, Nicole Wimmesberger, Rebekka Allen, Kerstin Meyer, Sabine Müller, Hanna Niese, Sina Polk, Barbara Reistle, Carolin Schuhmacher, Andreas von Ameln-Meyerhofer, Kim Winter, Dave Wirth, Winfried V Kern, Erik Farin-Glattacker, Siegbert Rieg

BackgroundNon-university hospitals are the major provider of inpatient care in Germany, serving 89% of acute care hospital beds. Although surveillance data on antimicrobial use in hospitals are widely available, data on prescription quality are rare.AimWe aimed to provide an in-depth analysis of antimicrobial prescribing patterns and quality in southwest German non-university hospitals.MethodsDuring 2021, we performed three point prevalence surveys (PPS) in 10 non-university hospitals, representing ca 10% of hospital beds in the federal state of Baden-Württemberg (11 million inhabitants). Demographic and clinical information were collected. We assessed the overall performance of 14 validated process quality indicators (QI) covering infection diagnostics, antimicrobial therapy and documentation.ResultsOf 8,560 patients analysed, 2,861 (33%) received at least one antimicrobial. Most (2,789, 80%) antimicrobial prescriptions were for therapeutic indications. Most frequently prescribed agents were beta-lactam/beta-lactamase inhibitors (1,120, 40%) in therapeutic and cefuroxime (269, 37%) in prophylactic indications. According to the World Health Organization's Access, Watch, Reserve classification, the Access-to-Watch ratio was 0.73. Overall adherence to QIs was low and varied substantially (27-93%), with documentation, possible streamlining and switching to oral therapy exhibiting the lowest fulfilment rates (< 50%).ConclusionThe results indicate a need to improve antimicrobial prescribing quality in non-university hospitals. The high prevalence of antimicrobial use in our setting underlines the demand for sustainable antimicrobial stewardship programmes in this sector. Our QI-based PPS approach can be used to identify key targets for future antimicrobial stewardship interventions. The results indicate a need for further legislation on antimicrobial stewardship.

背景非大学医院是德国住院治疗的主要提供者,为 89% 的急诊病床提供服务。尽管有关医院抗菌药物使用情况的监测数据广泛存在,但有关处方质量的数据却十分罕见。方法 2021 年,我们在 10 家非大学医院进行了三次点流行率调查 (PPS),这些医院约占巴登-符腾堡联邦州(1100 万居民)病床数的 10%。调查收集了人口和临床信息。我们评估了 14 项经过验证的流程质量指标(QI)的整体表现,其中包括感染诊断、抗菌药物治疗和文档记录。大多数(2789 个,80%)抗菌药处方都有治疗适应症。最常处方的药物是治疗用的β-内酰胺/β-内酰胺酶抑制剂(1120,40%)和预防用的头孢呋辛(269,37%)。根据世界卫生组织的 "获取、观察、储备 "分类,"获取-观察 "比率为 0.73。对质量指标的总体遵守率较低,且差异较大(27%-93%),其中文件记录、可能的简化和改用口服疗法的遵守率最低 (
{"title":"An in-depth analysis of antimicrobial prescription quality in 10 non-university hospitals, in southwest Germany, 2021.","authors":"Gesche Först, Roland Giesen, Geertje Fink, Matthias Sehlbrede, Nicole Wimmesberger, Rebekka Allen, Kerstin Meyer, Sabine Müller, Hanna Niese, Sina Polk, Barbara Reistle, Carolin Schuhmacher, Andreas von Ameln-Meyerhofer, Kim Winter, Dave Wirth, Winfried V Kern, Erik Farin-Glattacker, Siegbert Rieg","doi":"10.2807/1560-7917.ES.2024.29.46.2400156","DOIUrl":"10.2807/1560-7917.ES.2024.29.46.2400156","url":null,"abstract":"<p><p>BackgroundNon-university hospitals are the major provider of inpatient care in Germany, serving 89% of acute care hospital beds. Although surveillance data on antimicrobial use in hospitals are widely available, data on prescription quality are rare.AimWe aimed to provide an in-depth analysis of antimicrobial prescribing patterns and quality in southwest German non-university hospitals.MethodsDuring 2021, we performed three point prevalence surveys (PPS) in 10 non-university hospitals, representing ca 10% of hospital beds in the federal state of Baden-Württemberg (11 million inhabitants). Demographic and clinical information were collected. We assessed the overall performance of 14 validated process quality indicators (QI) covering infection diagnostics, antimicrobial therapy and documentation.ResultsOf 8,560 patients analysed, 2,861 (33%) received at least one antimicrobial. Most (2,789, 80%) antimicrobial prescriptions were for therapeutic indications. Most frequently prescribed agents were beta-lactam/beta-lactamase inhibitors (1,120, 40%) in therapeutic and cefuroxime (269, 37%) in prophylactic indications. According to the World Health Organization's Access, Watch, Reserve classification, the Access-to-Watch ratio was 0.73. Overall adherence to QIs was low and varied substantially (27-93%), with documentation, possible streamlining and switching to oral therapy exhibiting the lowest fulfilment rates (< 50%).ConclusionThe results indicate a need to improve antimicrobial prescribing quality in non-university hospitals. The high prevalence of antimicrobial use in our setting underlines the demand for sustainable antimicrobial stewardship programmes in this sector. Our QI-based PPS approach can be used to identify key targets for future antimicrobial stewardship interventions. The results indicate a need for further legislation on antimicrobial stewardship.</p>","PeriodicalId":12161,"journal":{"name":"Eurosurveillance","volume":"29 46","pages":""},"PeriodicalIF":9.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11565651/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Self-reported hepatitis A and B vaccination coverage among men who have sex with men (MSM), associated factors and vaccination recommendations in 43 countries of the WHO European Region: results from the European MSM Internet Survey, EMIS-2017. 世卫组织欧洲地区 43 个国家的男男性行为者 (MSM) 自我报告的甲型肝炎和乙型肝炎疫苗接种覆盖率、相关因素和疫苗接种建议:欧洲 MSM 互联网调查 EMIS-2017 的结果。
IF 9.9 2区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-11-01 DOI: 10.2807/1560-7917.ES.2024.29.45.2400100
Michael Brandl, Axel J Schmidt, Ulrich Marcus, Erika Duffell, Ettore Severi, Antons Mozalevskis, Anda Kivite-Urtane, Matthias An der Heiden, Sandra Dudareva

BackgroundHepatitis A and B vaccinations are recommended for men who have sex with men (MSM), given their increased risk of infection. However, data on vaccination programmes are scarce.AimTo use information on vaccination recommendations and vaccine uptake among MSM in the WHO European Region to guide prevention.MethodsFrom a large pan-European MSM Internet Survey (EMIS-2017), we analysed data on self-reported hepatitis A and B vaccination status by age, education, financial coping, settlement size, outness (disclosure of sexual behaviour), migration history and diagnosis with hepatitis C or HIV, using multivariable logistic regression. Additionally, we collected information on national hepatitis A and B vaccination recommendations.ResultsWe present data of 113,884 MSM, median age 36 years (IQR: 27-47). Vaccination for hepatitis A and B was recommended and free for MSM in 7 and 18 of 43 countries, respectively. Of all respondents, 48% (n = 50,966) reported ever being vaccinated against hepatitis A, and 53% (n = 56,889) against hepatitis B. Odds for being vaccinated against hepatitis A increased with outness ('out to (almost) all' aOR: 1.78, 95% CI: 1.72-1.85 vs 'out to none') and were higher in countries where vaccination was recommended and free for MSM (aOR: 2.22, 95% CI: 1.29-3.82 vs 'no recommendation'). Results for hepatitis B were similar (outness: aOR: 1.81, 95% CI: 1.75-1.88 and MSM-specific vaccination recommendation: aOR: 2.44, 95% CI: 1.54-3.85).ConclusionLarge proportions of MSM in Europe remain vulnerable to hepatitis A and B, despite available vaccination. Implementation of MSM-specific vaccination recommendations and greater efforts to improve the societal climate for MSM are needed to address gaps in vaccine coverage.

背景鉴于男男性行为者(MSM)的感染风险增加,建议他们接种甲型和乙型肝炎疫苗。方法在一项大型泛欧 MSM 互联网调查(EMIS-2017)中,我们使用多变量逻辑回归分析了按年龄、教育程度、经济状况、定居规模、出柜率(性行为披露)、移民史和丙型肝炎或艾滋病毒诊断结果分列的自我报告的甲型肝炎和乙型肝炎疫苗接种状况数据。此外,我们还收集了有关国家甲型肝炎和乙型肝炎疫苗接种建议的信息。结果我们提供了 113,884 名 MSM 的数据,他们的中位年龄为 36 岁(IQR:27-47)。在 43 个国家中,分别有 7 个和 18 个国家建议 MSM 免费接种甲型和乙型肝炎疫苗。在所有受访者中,48%(n = 50,966)表示曾经接种过甲型肝炎疫苗,53%(n = 56,889)表示曾经接种过乙型肝炎疫苗。78,95% CI:1.72-1.85 vs 'out to none'),并且在推荐 MSM 免费接种疫苗的国家接种率更高(aOR:2.22,95% CI:1.29-3.82 vs '无推荐')。乙型肝炎的结果类似(无推荐:aOR:1.81,95% CI:1.75-1.88;建议 MSM 接种:aOR:2.44,95% CI:1.54-3.85)。需要实施针对 MSM 的疫苗接种建议,并加大力度改善 MSM 的社会环境,以解决疫苗接种覆盖率不足的问题。
{"title":"Self-reported hepatitis A and B vaccination coverage among men who have sex with men (MSM), associated factors and vaccination recommendations in 43 countries of the WHO European Region: results from the European MSM Internet Survey, EMIS-2017.","authors":"Michael Brandl, Axel J Schmidt, Ulrich Marcus, Erika Duffell, Ettore Severi, Antons Mozalevskis, Anda Kivite-Urtane, Matthias An der Heiden, Sandra Dudareva","doi":"10.2807/1560-7917.ES.2024.29.45.2400100","DOIUrl":"10.2807/1560-7917.ES.2024.29.45.2400100","url":null,"abstract":"<p><p>BackgroundHepatitis A and B vaccinations are recommended for men who have sex with men (MSM), given their increased risk of infection. However, data on vaccination programmes are scarce.AimTo use information on vaccination recommendations and vaccine uptake among MSM in the WHO European Region to guide prevention.MethodsFrom a large pan-European MSM Internet Survey (EMIS-2017), we analysed data on self-reported hepatitis A and B vaccination status by age, education, financial coping, settlement size, outness (disclosure of sexual behaviour), migration history and diagnosis with hepatitis C or HIV, using multivariable logistic regression. Additionally, we collected information on national hepatitis A and B vaccination recommendations.ResultsWe present data of 113,884 MSM, median age 36 years (IQR: 27-47). Vaccination for hepatitis A and B was recommended and free for MSM in 7 and 18 of 43 countries, respectively. Of all respondents, 48% (n = 50,966) reported ever being vaccinated against hepatitis A, and 53% (n = 56,889) against hepatitis B. Odds for being vaccinated against hepatitis A increased with outness ('out to (almost) all' aOR: 1.78, 95% CI: 1.72-1.85 vs 'out to none') and were higher in countries where vaccination was recommended and free for MSM (aOR: 2.22, 95% CI: 1.29-3.82 vs 'no recommendation'). Results for hepatitis B were similar (outness: aOR: 1.81, 95% CI: 1.75-1.88 and MSM-specific vaccination recommendation: aOR: 2.44, 95% CI: 1.54-3.85).ConclusionLarge proportions of MSM in Europe remain vulnerable to hepatitis A and B, despite available vaccination. Implementation of MSM-specific vaccination recommendations and greater efforts to improve the societal climate for MSM are needed to address gaps in vaccine coverage.</p>","PeriodicalId":12161,"journal":{"name":"Eurosurveillance","volume":"29 45","pages":""},"PeriodicalIF":9.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11544724/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Have your say in the Eurosurveillance evaluation survey. 在欧洲监控评估调查中有你的发言权。
IF 9.9 2区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-11-01 DOI: 10.2807/1560-7917.ES.2024.29.48.2411289
{"title":"Have your say in the <i>Eurosurveillance</i> evaluation survey.","authors":"","doi":"10.2807/1560-7917.ES.2024.29.48.2411289","DOIUrl":"10.2807/1560-7917.ES.2024.29.48.2411289","url":null,"abstract":"","PeriodicalId":12161,"journal":{"name":"Eurosurveillance","volume":"29 48","pages":""},"PeriodicalIF":9.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11605799/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142750331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outbreak of paediatric myocarditis associated with parvovirus B19 infection in Italy, January to October 2024. 2024年1月至10月意大利与细小病毒B19感染相关的小儿心肌炎暴发
IF 9.9 2区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-11-01 DOI: 10.2807/1560-7917.ES.2024.29.48.2400746
Marco Poeta, Cristina Moracas, Francesca Ippolita Calò Carducci, Claudio Cafagno, Danilo Buonsenso, Marco Maglione, Sofia Sgubbi, Cecilia Liberati, Elisabetta Venturini, Giuseppe Limongelli, Felice Nunziata, Laura Petrarca, Claudia Mandato, Claudia Colomba, Alfredo Guarino

Acute myocarditis has risen among paediatric patients in Italy, with 65 clinically suspected cases reported by 12 centres in 2024, 32 linked to parvovirus B19 (B19V) infection. In 11 cases, B19V was not ruled out despite a concurrent European outbreak. Twenty-nine children required intensive care; eight fatalities occurred. While effective for both severe B19V infection and myocarditis, intravenous immunoglobulins were given in only one-third of cases. These findings highlight the need for timely diagnosis, stronger surveillance, and standardised treatment protocols.

意大利儿科急性心肌炎患者有所增加,2024年12个中心报告了65例临床疑似病例,其中32例与细小病毒B19 (B19V)感染有关。在11例病例中,尽管欧洲同时爆发了B19V,但仍未排除。29名儿童需要重症监护;造成8人死亡。虽然对严重B19V感染和心肌炎都有效,但静脉注射免疫球蛋白仅对三分之一的病例有效。这些发现强调了及时诊断、加强监测和标准化治疗方案的必要性。
{"title":"Outbreak of paediatric myocarditis associated with parvovirus B19 infection in Italy, January to October 2024.","authors":"Marco Poeta, Cristina Moracas, Francesca Ippolita Calò Carducci, Claudio Cafagno, Danilo Buonsenso, Marco Maglione, Sofia Sgubbi, Cecilia Liberati, Elisabetta Venturini, Giuseppe Limongelli, Felice Nunziata, Laura Petrarca, Claudia Mandato, Claudia Colomba, Alfredo Guarino","doi":"10.2807/1560-7917.ES.2024.29.48.2400746","DOIUrl":"10.2807/1560-7917.ES.2024.29.48.2400746","url":null,"abstract":"<p><p>Acute myocarditis has risen among paediatric patients in Italy, with 65 clinically suspected cases reported by 12 centres in 2024, 32 linked to parvovirus B19 (B19V) infection. In 11 cases, B19V was not ruled out despite a concurrent European outbreak. Twenty-nine children required intensive care; eight fatalities occurred. While effective for both severe B19V infection and myocarditis, intravenous immunoglobulins were given in only one-third of cases. These findings highlight the need for timely diagnosis, stronger surveillance, and standardised treatment protocols.</p>","PeriodicalId":12161,"journal":{"name":"Eurosurveillance","volume":"29 48","pages":""},"PeriodicalIF":9.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11605801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142750351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment uptake among notified cases of hepatitis C virus infection in Norway, 1990 to 2022: a registry-based study to monitor progress towards elimination. 1990年至2022年挪威丙型肝炎病毒感染通报病例的接受治疗情况:一项以登记为基础的研究,旨在监测消除丙型肝炎的进展情况。
IF 9.9 2区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-11-01 DOI: 10.2807/1560-7917.ES.2024.29.46.2400180
Robert Whittaker, Håvard Midgard, Olav Dalgard, Hilde Kløvstad

BackgroundHepatitis C virus (HCV) infection is targeted for elimination as a public health threat by 2030. The World Health Organization goal for treatment uptake is ≥ 80% among cases diagnosed with an active HCV infection (RNA- or core antigen-positive), maintained for 2 years.AimTo calculate treatment uptake, time from diagnosis to treatment start and complete treatment dispensation among notified cases of HCV infection in Norway.MethodWe linked national data on notified cases diagnosed from 1990-2022 to dispensed prescriptions for HCV treatment from January 2004-February 2023 and data on residence status at the end of 2022. We described treatment uptake by demographic and epidemiological characteristics. We calculated the median number of months from diagnosis to treatment start by year. For direct-acting antiviral treatment periods, complete dispensation was based on the treatment and number of defined daily doses.ResultsAmong 12,178 notified cases that had an active infection at diagnosis and were still resident, 10,091 (83%) had received treatment. Uptake among resident cases was > 80% in 2021 and 2022. The median number of months from diagnosis to treatment decreased over time to 3 (interquartile range: 1-5) among cases diagnosed in 2021 and 2022. From 2015-22, 89-93% of direct-acting antiviral treatment periods annually had complete treatment dispensed.ConclusionNorway has achieved the elimination goal for treatment uptake among notified cases diagnosed with an active HCV infection. This highlights the benefit of a strategy that includes unrestricted, simplified and integrated treatment options.

背景丙型肝炎病毒(HCV)感染是一种公共卫生威胁,目标是到 2030 年消除这种感染。方法我们将1990年至2022年期间确诊的通报病例的全国数据与2004年1月至2023年2月期间的HCV治疗处方以及2022年底的居住状况数据联系起来。我们根据人口统计学和流行病学特征描述了接受治疗的情况。我们按年份计算了从诊断到开始治疗的月数中位数。对于直接作用抗病毒治疗期,根据治疗方法和规定的每日剂量数来确定是否完成治疗。 结果在诊断时有活动性感染且仍居住在当地的 12,178 例通知病例中,10,091 例(83%)接受了治疗。2021 年和 2022 年,常住病例中接受治疗的比例大于 80%。在 2021 年和 2022 年确诊的病例中,从确诊到接受治疗的中位月数随时间推移降至 3 个月(四分位数间距:1-5)。从 2015 年到 2022 年,每年有 89%-93% 的直接作用抗病毒治疗期获得了完整的治疗。这凸显了包括无限制、简化和综合治疗方案在内的战略的益处。
{"title":"Treatment uptake among notified cases of hepatitis C virus infection in Norway, 1990 to 2022: a registry-based study to monitor progress towards elimination.","authors":"Robert Whittaker, Håvard Midgard, Olav Dalgard, Hilde Kløvstad","doi":"10.2807/1560-7917.ES.2024.29.46.2400180","DOIUrl":"10.2807/1560-7917.ES.2024.29.46.2400180","url":null,"abstract":"<p><p>BackgroundHepatitis C virus (HCV) infection is targeted for elimination as a public health threat by 2030. The World Health Organization goal for treatment uptake is ≥ 80% among cases diagnosed with an active HCV infection (RNA- or core antigen-positive), maintained for 2 years.AimTo calculate treatment uptake, time from diagnosis to treatment start and complete treatment dispensation among notified cases of HCV infection in Norway.MethodWe linked national data on notified cases diagnosed from 1990-2022 to dispensed prescriptions for HCV treatment from January 2004-February 2023 and data on residence status at the end of 2022. We described treatment uptake by demographic and epidemiological characteristics. We calculated the median number of months from diagnosis to treatment start by year. For direct-acting antiviral treatment periods, complete dispensation was based on the treatment and number of defined daily doses.ResultsAmong 12,178 notified cases that had an active infection at diagnosis and were still resident, 10,091 (83%) had received treatment. Uptake among resident cases was > 80% in 2021 and 2022. The median number of months from diagnosis to treatment decreased over time to 3 (interquartile range: 1-5) among cases diagnosed in 2021 and 2022. From 2015-22, 89-93% of direct-acting antiviral treatment periods annually had complete treatment dispensed.ConclusionNorway has achieved the elimination goal for treatment uptake among notified cases diagnosed with an active HCV infection. This highlights the benefit of a strategy that includes unrestricted, simplified and integrated treatment options.</p>","PeriodicalId":12161,"journal":{"name":"Eurosurveillance","volume":"29 46","pages":""},"PeriodicalIF":9.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11565653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antibiotic consumption patterns in older adults: a comparative study of people 65 years and older in and outside nursing homes, Belgium, 2016 to 2022. 老年人的抗生素消费模式:2016 年至 2022 年对比利时养老院内外 65 岁及以上老年人的比较研究。
IF 9.9 2区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-11-01 DOI: 10.2807/1560-7917.ES.2024.29.46.2400148
Moira Kelly, Marc de Falleur, El Maati Allaoui, Laura Bonacini, Boudewijn Catry, Katrien Latour, Lucy Catteau

BackgroundInappropriate antimicrobial consumption (AMC) drives the emergence of antimicrobial resistance. Institutionalised, older populations are associated with antimicrobial treatments of longer duration and broader spectrum than recommended, higher rates of multidrug-resistant infections and poorer outcomes for resistant infections. Yet systematic, national monitoring of AMC in nursing home (NH) residents is lacking.AimTo perform a retrospective analysis of antibiotic consumption in Belgian NHs, we compared analogous populations inside and outside NHs. We aimed to provide a blueprint for establishing surveillance of NH AMC, based on national reimbursement data.MethodsThe National Institute for Health and Disability Insurance supplied reimbursement AMC data for outpatients from 2016 to 2022. Data were classified by the Anatomical Therapeutic Chemical system, expressed as defined daily doses (DDD) and aggregated by prescription month, patient age, sex and residency inside/outside a NH. The number of ensured beneficiaries, aggregated by the same demographic variables, was collected from the Intermutualistic Agency. We compared the DDDs per 1,000 beneficiaries per day, along with secondary metrics for national and international targets for analogous populations inside and outside NHs.ResultsTotal antibiotic consumption decreased in both populations but remained twofold higher in NH residents. Proxy prescription quality metrics were consistently less favourable within NHs and diverged further during the COVID-19 pandemic. Distinct consumption patterns and greater seasonal fluctuations were observed in NH residents.ConclusionGiven the different infection risks and higher antibiotic consumption of NH residents, AMC surveillance and antimicrobial stewardship efforts targeting this fragile population are needed.

背景不适当的抗菌药物使用(AMC)会导致抗菌药物耐药性的产生。养老院中的老年人群使用抗菌药物的时间比推荐时间更长、范围更广,耐多药感染率更高,耐药感染的治疗效果更差。为了对比利时养老院的抗生素使用情况进行回顾性分析,我们对养老院内外的类似人群进行了比较。我们的目的是根据国家报销数据,为建立对国家卫生院AMC的监控提供一个蓝图。方法国家健康和残疾保险研究所提供了2016年至2022年门诊病人的AMC报销数据。数据按解剖治疗化学系统分类,以定义日剂量(DDD)表示,并按处方月份、患者年龄、性别和居住地(国家卫生机构内/外)汇总。根据相同的人口统计学变量汇总的受保受益人数量是从互助机构收集的。我们比较了国家卫生机构内外类似人群每天每千名受益人的抗生素使用量,以及国家和国际目标的二级指标。结果两种人群的抗生素总消耗量都有所下降,但国家卫生机构居民的抗生素消耗量仍然高出两倍。国家卫生机构内的替代处方质量指标一直较低,在 COVID-19 大流行期间,这些指标的差异进一步扩大。结论鉴于北卡罗来纳州居民具有不同的感染风险和较高的抗生素消耗量,因此需要针对这一脆弱人群开展 AMC 监测和抗菌药物管理工作。
{"title":"Antibiotic consumption patterns in older adults: a comparative study of people 65 years and older in and outside nursing homes, Belgium, 2016 to 2022.","authors":"Moira Kelly, Marc de Falleur, El Maati Allaoui, Laura Bonacini, Boudewijn Catry, Katrien Latour, Lucy Catteau","doi":"10.2807/1560-7917.ES.2024.29.46.2400148","DOIUrl":"10.2807/1560-7917.ES.2024.29.46.2400148","url":null,"abstract":"<p><p>BackgroundInappropriate antimicrobial consumption (AMC) drives the emergence of antimicrobial resistance. Institutionalised, older populations are associated with antimicrobial treatments of longer duration and broader spectrum than recommended, higher rates of multidrug-resistant infections and poorer outcomes for resistant infections. Yet systematic, national monitoring of AMC in nursing home (NH) residents is lacking.AimTo perform a retrospective analysis of antibiotic consumption in Belgian NHs, we compared analogous populations inside and outside NHs. We aimed to provide a blueprint for establishing surveillance of NH AMC, based on national reimbursement data.MethodsThe National Institute for Health and Disability Insurance supplied reimbursement AMC data for outpatients from 2016 to 2022. Data were classified by the Anatomical Therapeutic Chemical system, expressed as defined daily doses (DDD) and aggregated by prescription month, patient age, sex and residency inside/outside a NH. The number of ensured beneficiaries, aggregated by the same demographic variables, was collected from the Intermutualistic Agency. We compared the DDDs per 1,000 beneficiaries per day, along with secondary metrics for national and international targets for analogous populations inside and outside NHs.ResultsTotal antibiotic consumption decreased in both populations but remained twofold higher in NH residents. Proxy prescription quality metrics were consistently less favourable within NHs and diverged further during the COVID-19 pandemic. Distinct consumption patterns and greater seasonal fluctuations were observed in NH residents.ConclusionGiven the different infection risks and higher antibiotic consumption of NH residents, AMC surveillance and antimicrobial stewardship efforts targeting this fragile population are needed.</p>","PeriodicalId":12161,"journal":{"name":"Eurosurveillance","volume":"29 46","pages":""},"PeriodicalIF":9.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11565649/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Likelihood of HIV and recent bacterial sexually transmitted infections among transgender and non-binary individuals in 20 European countries, October 2023 to April 2024. 2023年10月至2024年4月,20个欧洲国家跨性别者和非二元性个体中HIV和近期细菌性传播感染的可能性
IF 9.9 2区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-11-01 DOI: 10.2807/1560-7917.ES.2024.29.48.2400347
Haoyi Wang, Johann Kolstee, Jules L Casalini, Samira Hakim, Hanne Ml Zimmermann, Kai J Jonas

BackgroundGlobal data highlight the disproportionate burden of HIV and sexually transmitted infections (STIs) among transgender individuals. However, scant data exist for both transgender and non-binary individuals in European HIV/STI surveillance.AimTo assess self-reported prevalence of HIV and bacterial STIs (syphilis, gonorrhoea, chlamydia) in the past 6 months among transgender and non-binary individuals, comparing the likelihoods of recent STIs between groups.MethodsUsing data from the cross-sectional PROTECT survey conducted in 20 European countries from October 2023 to April 2024, we analysed a subset of 452 participants, 178 transgender and 274 non-binary individuals. Logistic regression was used to compare the risk of each recent bacterial STI, and Poisson regression to compare the risk of the number of recent STIs.ResultsAmong transgender individuals, 5 (2.8%) self-reported HIV infection, and recent STI prevalence was 6.7% for syphilis, 15.6% for gonorrhoea and 19.6% for chlamydia. For non-binary individuals, 15 (5.5%) self-reported HIV infection and recent STI prevalence was 15.0% for syphilis, 18.7% for gonorrhoea and 20.8% for chlamydia. Non-binary individuals had significantly higher risk for syphilis (aOR: 1.81; 95% CI: 1.01-4.05) and multiple recent STIs (aOR: 1.46; 95% CI: 1.11-1.91) compared with transgender individuals.ConclusionWhile both transgender and non-binary individuals showed high self-reported prevalence of HIV and bacterial STIs, non-binary individuals showed greater prevalence of STIs, particularly syphilis. Efforts aimed at HIV/STI prevention and surveillance should encourage inclusion of those who identify as non-binary and other gender-diverse individuals alongside transgender individuals to enhance the provision of tailored prevention and treatment services in Europe.

全球数据强调了跨性别人群中不成比例的艾滋病毒和性传播感染负担。然而,在欧洲的艾滋病毒/性传播感染监测中,跨性别者和非双性恋者的数据很少。目的评估跨性别者和非双性恋者在过去6个月内自我报告的HIV和细菌性传播感染(梅毒、淋病、衣原体)的流行情况,比较两组之间最近发生性传播感染的可能性。方法使用从2023年10月至2024年4月在20个欧洲国家进行的横断面PROTECT调查的数据,我们分析了452名参与者,178名跨性别者和274名非二元个体。采用Logistic回归比较各近期细菌性性传播感染的风险,采用泊松回归比较近期性传播感染数量的风险。结果在跨性别人群中,有5人(2.8%)自我报告感染了HIV,最近的性传播感染患病率为梅毒6.7%,淋病15.6%,衣原体19.6%。在非二元个体中,15人(5.5%)自我报告艾滋病毒感染和近期性传播感染的患病率为梅毒15.0%,淋病18.7%,衣原体20.8%。非二元个体患梅毒的风险显著增高(aOR: 1.81;95% CI: 1.01-4.05)和近期多发性传播感染(aOR: 1.46;95% CI: 1.11-1.91)。结论跨性别者和非二元性人群的HIV和细菌性性传播感染自述率均较高,而非二元性人群的性传播感染(尤其是梅毒)自述率较高。旨在预防和监测艾滋病毒/性传播感染的努力应鼓励将那些认定为非二元和其他性别多样化的个人与跨性别者一起纳入,以加强在欧洲提供量身定制的预防和治疗服务。
{"title":"Likelihood of HIV and recent bacterial sexually transmitted infections among transgender and non-binary individuals in 20 European countries, October 2023 to April 2024.","authors":"Haoyi Wang, Johann Kolstee, Jules L Casalini, Samira Hakim, Hanne Ml Zimmermann, Kai J Jonas","doi":"10.2807/1560-7917.ES.2024.29.48.2400347","DOIUrl":"10.2807/1560-7917.ES.2024.29.48.2400347","url":null,"abstract":"<p><p>BackgroundGlobal data highlight the disproportionate burden of HIV and sexually transmitted infections (STIs) among transgender individuals. However, scant data exist for both transgender and non-binary individuals in European HIV/STI surveillance.AimTo assess self-reported prevalence of HIV and bacterial STIs (syphilis, gonorrhoea, chlamydia) in the past 6 months among transgender and non-binary individuals, comparing the likelihoods of recent STIs between groups.MethodsUsing data from the cross-sectional PROTECT survey conducted in 20 European countries from October 2023 to April 2024, we analysed a subset of 452 participants, 178 transgender and 274 non-binary individuals. Logistic regression was used to compare the risk of each recent bacterial STI, and Poisson regression to compare the risk of the number of recent STIs.ResultsAmong transgender individuals, 5 (2.8%) self-reported HIV infection, and recent STI prevalence was 6.7% for syphilis, 15.6% for gonorrhoea and 19.6% for chlamydia. For non-binary individuals, 15 (5.5%) self-reported HIV infection and recent STI prevalence was 15.0% for syphilis, 18.7% for gonorrhoea and 20.8% for chlamydia. Non-binary individuals had significantly higher risk for syphilis (aOR: 1.81; 95% CI: 1.01-4.05) and multiple recent STIs (aOR: 1.46; 95% CI: 1.11-1.91) compared with transgender individuals.ConclusionWhile both transgender and non-binary individuals showed high self-reported prevalence of HIV and bacterial STIs, non-binary individuals showed greater prevalence of STIs, particularly syphilis. Efforts aimed at HIV/STI prevention and surveillance should encourage inclusion of those who identify as non-binary and other gender-diverse individuals alongside transgender individuals to enhance the provision of tailored prevention and treatment services in Europe.</p>","PeriodicalId":12161,"journal":{"name":"Eurosurveillance","volume":"29 48","pages":""},"PeriodicalIF":9.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11605802/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142750335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Detection of circulating type 3 vaccine-derived polioviruses in French Guiana, May to August 2024. 2024 年 5 月至 8 月法属圭亚那 3 型疫苗衍生脊髓灰质炎病毒的检测。
IF 9.9 2区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-11-01 DOI: 10.2807/1560-7917.ES.2024.29.45.2400705
Stéphanie Raffestin, Ambre Tinard, Antoine Enfissi, Marie-Line Joffret, Timothée Lichtenstein, Sourakhata Tirera, Laura Zanetti, Marie Barrau, Francky Mubenga, Adrien Ortelli, Christophe N Peyrefitte, Anne Lavergne, Dominique Rousset, Maël Bessaud

Circulating type 3 vaccine-derived polioviruses (cVDPV3s) were detected in three wastewater samples collected in French Guiana from May through August 2024. As the oral polio vaccine is not used in French Guiana, this event involved an import either of cVDPV3s themselves or of a vaccine strain from which the cVDPV3s emerged in French Guiana. This highlights the importance of environmental surveillance for the detection of silent poliovirus circulation. Eliminating any pockets of cVDPVs is crucial for the polio eradication programme.

2024 年 5 月至 8 月期间,在法属圭亚那采集的三份废水样本中检测到了 3 型疫苗衍生脊灰病毒(cVDPV3s)。由于法属圭亚那不使用口服脊髓灰质炎疫苗,因此这一事件要么是 cVDPV3s 本身的输入,要么是在法属圭亚那出现 cVDPV3s 的疫苗株的输入。这凸显了环境监测对检测无声脊灰病毒传播的重要性。消除任何小范围的 cVDPVs 对于根除脊髓灰质炎计划至关重要。
{"title":"Detection of circulating type 3 vaccine-derived polioviruses in French Guiana, May to August 2024.","authors":"Stéphanie Raffestin, Ambre Tinard, Antoine Enfissi, Marie-Line Joffret, Timothée Lichtenstein, Sourakhata Tirera, Laura Zanetti, Marie Barrau, Francky Mubenga, Adrien Ortelli, Christophe N Peyrefitte, Anne Lavergne, Dominique Rousset, Maël Bessaud","doi":"10.2807/1560-7917.ES.2024.29.45.2400705","DOIUrl":"10.2807/1560-7917.ES.2024.29.45.2400705","url":null,"abstract":"<p><p>Circulating type 3 vaccine-derived polioviruses (cVDPV3s) were detected in three wastewater samples collected in French Guiana from May through August 2024. As the oral polio vaccine is not used in French Guiana, this event involved an import either of cVDPV3s themselves or of a vaccine strain from which the cVDPV3s emerged in French Guiana. This highlights the importance of environmental surveillance for the detection of silent poliovirus circulation. Eliminating any pockets of cVDPVs is crucial for the polio eradication programme.</p>","PeriodicalId":12161,"journal":{"name":"Eurosurveillance","volume":"29 45","pages":""},"PeriodicalIF":9.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11544717/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Agile, on-demand wastewater surveillance of virus infections to support pandemic and outbreak response in Rotterdam-Rijnmond, the Netherlands, 2020 to 2022. 2020 年至 2022 年,在荷兰鹿特丹-莱茵蒙德对病毒感染进行灵活、按需的废水监测,以支持大流行病和疫情的应对工作。
IF 9.9 2区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-11-01 DOI: 10.2807/1560-7917.ES.2024.29.47.2400055
Emma Besijn, Jane Whelan, Paul Bijkerk, Gregorius J Sips, Jeroen Langeveld, Ray W Izquierdo-Lara, Elvira van Baarle, Remy Schilperoort, Marion P G Koopmans, Miranda de Graaf, Gertjan Medema, Ewout Fanoy

BackgroundWastewater surveillance may support early and comprehensive detection of infectious diseases' community transmission, particularly in settings where other health surveillance systems provide biased or limited information. Amid the SARS-CoV-2 pandemic, deploying passive samplers to monitor targeted populations gained importance. Evaluation of the added public health value of this approach in the field can support its broader adoption.AimWe aimed to assess the feasibility and utility of on-demand wastewater surveillance, employing passive samplers, for SARS-CoV-2 and monkeypox virus (MPXV) in small/targeted populations, also considering ethical aspects.MethodsPilot case studies in the Rotterdam-Rijnmond region were used for a systematic assessment of the feasibility and utility of wastewater monitoring of SARS-CoV-2 (variants) and MPXV using passive sampling. Each case study was instigated by actual questions from the Public Health Service about disease transmission.ResultsCase study results demonstrated the feasibility and utility of on-demand wastewater surveillance with successful identification of a local peak in SARS-CoV-2 transmission, early detection of wider Omicron variant transmission after the first case was reported, as well as indication of no emerging local MPXV transmission. Ethical considerations led to the abandonment of one case study involving a displaced population.ConclusionsThe study confirms the feasibility and utility of passive sampling for real-time infectious disease surveillance, at desired spatiotemporal resolution. Ethical concerns and operational challenges were identified, highlighting the need for early stakeholder engagement and ethical guideline adherence. The method could be used to study under-surveyed populations and be extended beyond SARS-CoV-2 and MPXV to other pathogens.

背景废水监测可支持对传染病的社区传播进行早期和全面检测,尤其是在其他卫生监测系统提供的信息存在偏差或有限的情况下。在 SARS-CoV-2 大流行期间,部署被动采样器监测目标人群变得越来越重要。我们的目的是评估在小规模/目标人群中使用被动采样器对 SARS-CoV-2 和猴痘病毒 (MPXV) 进行按需废水监测的可行性和实用性,同时考虑伦理方面的问题。方法在鹿特丹-莱茵蒙德地区进行试点案例研究,系统评估使用被动采样对 SARS-CoV-2 和 MPXV 进行废水监测的可行性和实用性。结果案例研究结果表明了按需废水监测的可行性和实用性,成功确定了当地的 SARS-CoV-2 传播高峰,在报告首例病例后及早发现了更广泛的 Omicron 变种传播,并表明当地没有出现 MPXV 传播。由于伦理方面的考虑,一项涉及流离失所人群的个案研究被放弃。研究发现了伦理方面的问题和操作上的挑战,强调了利益相关者尽早参与和遵守伦理准则的必要性。该方法可用于研究调查不足的人群,并可从 SARS-CoV-2 和 MPXV 扩展到其他病原体。
{"title":"Agile, on-demand wastewater surveillance of virus infections to support pandemic and outbreak response in Rotterdam-Rijnmond, the Netherlands, 2020 to 2022.","authors":"Emma Besijn, Jane Whelan, Paul Bijkerk, Gregorius J Sips, Jeroen Langeveld, Ray W Izquierdo-Lara, Elvira van Baarle, Remy Schilperoort, Marion P G Koopmans, Miranda de Graaf, Gertjan Medema, Ewout Fanoy","doi":"10.2807/1560-7917.ES.2024.29.47.2400055","DOIUrl":"10.2807/1560-7917.ES.2024.29.47.2400055","url":null,"abstract":"<p><p>BackgroundWastewater surveillance may support early and comprehensive detection of infectious diseases' community transmission, particularly in settings where other health surveillance systems provide biased or limited information. Amid the SARS-CoV-2 pandemic, deploying passive samplers to monitor targeted populations gained importance. Evaluation of the added public health value of this approach in the field can support its broader adoption.AimWe aimed to assess the feasibility and utility of on-demand wastewater surveillance, employing passive samplers, for SARS-CoV-2 and monkeypox virus (MPXV) in small/targeted populations, also considering ethical aspects.MethodsPilot case studies in the Rotterdam-Rijnmond region were used for a systematic assessment of the feasibility and utility of wastewater monitoring of SARS-CoV-2 (variants) and MPXV using passive sampling. Each case study was instigated by actual questions from the Public Health Service about disease transmission.ResultsCase study results demonstrated the feasibility and utility of on-demand wastewater surveillance with successful identification of a local peak in SARS-CoV-2 transmission, early detection of wider Omicron variant transmission after the first case was reported, as well as indication of no emerging local MPXV transmission. Ethical considerations led to the abandonment of one case study involving a displaced population.ConclusionsThe study confirms the feasibility and utility of passive sampling for real-time infectious disease surveillance, at desired spatiotemporal resolution. Ethical concerns and operational challenges were identified, highlighting the need for early stakeholder engagement and ethical guideline adherence. The method could be used to study under-surveyed populations and be extended beyond SARS-CoV-2 and MPXV to other pathogens.</p>","PeriodicalId":12161,"journal":{"name":"Eurosurveillance","volume":"29 47","pages":""},"PeriodicalIF":9.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11583307/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142686368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Eurosurveillance
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1